Marzetti and TABASCO Brand Unite to Unleash the Ultimate Spicy Ranch

Marzetti and TABASCO Brand Unite to Unleash the Ultimate Spicy Ranch

Marzetti® Spicy Ranch Seasoned with TABASCO® Sauce brings the perfect blend of heat and creaminess to fans who refuse to settle.

COLUMBUS, Ohio–(BUSINESS WIRE)–
For over a century, Marzetti and TABASCO® Brand have been crafting craveable flavors. Now, for the first time ever, these two trusted brands have teamed up to unleash the ultimate refrigerated spicy ranch—a rich, creamy Marzetti ranch fused with the unmistakable flavor and excitement of TABASCO® Pepper Sauce.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325933069/en/

Marzetti® Spicy Ranch Seasoned with TABASCO® Sauce brings the perfect blend of heat and creaminess to fans who refuse to settle.

Marzetti® Spicy Ranch Seasoned with TABASCO® Sauce brings the perfect blend of heat and creaminess to fans who refuse to settle.

With spicy food booming and ranch remaining America’s #1 dressing, consumers are increasingly seeking higher quality, better-tasting products that deliver flavor without compromise. Found in the fresh produce aisle, this refrigerated dressing is made with quality ingredients, no preservatives and no artificial flavors, bringing a much-needed punch of flavor to the refrigerated dressings category. Perfectly balancing the creaminess of Marzetti Ranch with the flavor and heat of TABASCO® Sauce, this dressing is artfully blended to elevate—not overpower—your favorite pizza, wings, fries, salads, burgers, tacos and more.

“Hot sauce and ranch fans take their favorites seriously. Consumers aren’t just chasing heat; they crave balance and depth of flavor, and that’s exactly what our culinary team delivered,” said Brett Castle, Vice President of Brand Management at T. Marzetti Company. “TABASCO® Brand is the highest-trusted name in heat and pepper expertise, making it the ideal partner for us to bring a spicy ranch to the refrigerated dressings category.”

This spicy ranch brings a twist to the traditional refrigerated dressing space and proves that ingredient-conscious consumers don’t have to compromise on flavor. The collaboration, which was facilitated by IMG Licensing, will be a game-changer for ranch lovers and heat seekers alike. It’s a new era for indulgent taste.

“For over 150 years, TABASCO® Brand has made food more exciting with our products’ signature kick of heat and flavor,” added Kate Neuhaus, Director of Global Marketing Communications at McIlhenny Company. “We’re thrilled to collaborate with Marzetti to bring our pepper expertise into the world of refrigerated ranch dressings and can’t wait to see how fans use it to make their favorite foods even more exciting.”

Fans can find Marzetti Spicy Ranch Seasoned with TABASCO® Sauce in the refrigerated produce section at Kroger nationwide now, with availability at Walmart and other local grocery stores by May.

To learn more and stay up to date on additional distribution, visit https://marzetti.com/products/spicy-ranch-seasoned-with-tabasco-sauce/.

About T. Marzetti Company:

T. Marzetti Company manufactures and sells specialty food products. Our retail brands include Marzetti® dressings and dips, New York Bakery garlic breads, and Sister Schubert’s® dinner rolls, in addition to exclusive license agreements for Olive Garden® dressings, Chick-fil-A® sauces and dressings, Buffalo Wild Wings® sauces, Arby’s® sauces, Subway® sauces, and Texas Roadhouse® steak sauces and frozen rolls. Our foodservice business supplies sauces, dressings, breads, and pasta to many of the top restaurant chains in the United States.

At T. Marzetti, our mission is to make every meal better through high-quality, flavorful food. Led by our purpose, to nourish growth with all that we do, our 3,800 team members are dedicated to creating great tasting food and cultivating deep and lasting relationships.

T. Marzetti Company is a wholly owned subsidiary of Lancaster Colony Corporation (NASDAQ: LANC).

About McIlhenny Company & TABASCO® Brand

From our home on Avery Island, Louisiana, McIlhenny Company produces TABASCO® Brand products, including the legendary TABASCO® Original Red Sauce. A household and restaurant staple around the world, TABASCO® Sauce is sold in more than 195 countries and territories and labeled in more than 36 languages and dialects.

With more than 155 years of pepper expertise, our family-owned and operated company is constantly experimenting with new flavors and products to carry on our legacy of exciting the world’s most popular food and drinks. Our core range of pepper sauces includes TABASCO® Original Red Sauce, TABASCO® Jalapeño Sauce, TABASCO® Chipotle Sauce, TABASCO® Sweet Chili Sauce, TABASCO® Sriracha, TABASCO® Habanero Sauce, TABASCO® Scorpion Sauce, TABASCO® Buffalo Style Sauce, and our new TABASCO® Salsa Picante.

To learn more about how we #LightThingsUp please visit us at www.tabasco.com or follow us on Facebook, Instagram, X, TikTok and LinkedIn.

TABASCO® Brand and the DIAMOND and BOTTLE LOGOS are trademarks of and licensed by McIlhenny Company, Avery Island, Louisiana 70513 USA.

About IMG:

IMG is a global sports, events and representation company. It is a leader in rights management, multi-channel content production and distribution, consultancy and fan engagement; owns, produces and commercially represents hundreds of live events and experiences; and manages licensing programs for the world’s best-known brands and trademarks.

Media Contacts:

Belle Communication

Violet Pocock

[email protected]

(239) 974-6764

T. Marzetti Company

Alysa Spittle

[email protected]

KEYWORDS: United States North America Ohio

INDUSTRY KEYWORDS: Food/Beverage Retail

MEDIA:

Photo
Photo
Marzetti® Spicy Ranch Seasoned with TABASCO® Sauce brings the perfect blend of heat and creaminess to fans who refuse to settle.
Photo
Photo
Marzetti® Spicy Ranch Seasoned with TABASCO® Sauce brings the perfect blend of heat and creaminess to fans who refuse to settle.
Logo
Logo

AEye to Participate in Bank of America’s 2025 Global Automotive Summit

AEye to Participate in Bank of America’s 2025 Global Automotive Summit

PLEASANTON, Calif.–(BUSINESS WIRE)–
AEye, Inc. (Nasdaq: LIDR), a global leader in adaptive, high-performance lidar solutions, today announced that its executive management team, CEO Matt Fisch and CFO Conor Tierney, will participate in the following conference:

Bank of America’s 2025 Global Automotive Summit

Location: New York, NY

Date: April 16, 2025

Format: One-on-one and small group meetings

If you plan to attend this conference and wish to meet with AEye, please contact [email protected].

The latest investor materials are available under the Investor Relations section of AEye’s website at https://investors.aeye.ai/news-events/events-presentations.

About AEye

AEye’s unique software-defined lidar solution enables advanced driver-assistance, vehicle autonomy, smart infrastructure, and logistics applications that save lives and propel the future of transportation and mobility. AEye’s 4Sight™ Intelligent Sensing Platform, with its adaptive sensor-based operating system, focuses on what matters most: delivering faster, more accurate, and reliable information. AEye’s 4Sight™ products, built on this platform, are ideal for dynamic applications which require precise measurement imaging to ensure safety and performance.

Investor Relations Contacts

Agency Contact

Financial Profiles, Inc.

Evan Niu, CFA

[email protected]

310-622-8243

Company Contact

AEye, Inc. Investor Relations

[email protected]

925-400-4366

KEYWORDS: United States North America California New York

INDUSTRY KEYWORDS: Vehicle Technology Automotive Technology Transport Logistics/Supply Chain Management Software

MEDIA:

Logo
Logo

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference.

The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET – Track 1.

The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

Jeuveau® and Nuceiva®, are registered trademarks and Evolysse is a trademark of Evolus, Inc.

Investors:

Nareg Sagherian, Vice President, Head of Global Investor Relations and Corporate Communications

Phone: (248) 202-9267

Email: [email protected]

Media:

Email: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Cosmetics Retail Luxury Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Cannae Holdings, Inc. Announces Support for Dun & Bradstreet Sale Transaction, An Increase in Share Buyback Authorization and a Transition to a Declassified Board

Cannae Holdings, Inc. Announces Support for Dun & Bradstreet Sale Transaction, An Increase in Share Buyback Authorization and a Transition to a Declassified Board

~ Dun & Bradstreet Sale Will Provide ~$632 Million of Cash Proceeds to Cannae ~

~ Cannae Increases Share Buyback Authorization to 23 Million Shares and Reiterates Priority for Capital Return to Shareholders~

~ Cannae Board to Transition to a Declassified Board ~

LAS VEGAS–(BUSINESS WIRE)–
Cannae Holdings, Inc. (NYSE: CNNE) (“Cannae” or the “Company”) today announced its support for the sale of Dun & Bradstreet (“DNB”), increased its share buyback authorization to approximately 23 million shares, and plans to transition to a declassified board with annual elections.

William P. Foley, II, CEO and Chairman of Cannae, commented, “I would like to congratulate the DNB Board of Directors and management team on their recent announcement of the sale of the company and affirm Cannae’s support for the sale transaction through a Voting and Support Agreement. DNB is Cannae’s largest investment as Cannae holds 69.1 million shares, or approximately 16% of DNB shares.”

At the announced transaction value, Cannae would realize approximately $632 million. The transaction is expected to close in the third quarter of 2025, subject to Dun & Bradstreet shareholder approval, regulatory clearances and other customary closing conditions. The Voting and Support Agreement allows Cannae to sell up to 10 million DNB shares ahead of the transaction’s closing. The Company expects that a significant portion of proceeds received from the DNB transaction will be returned to shareholders in the form of share buybacks.

The Company today announced that its Board of Directors has authorized a three-year stock repurchase program, effective March 24, 2025, under which the Company may repurchase up to 10 million additional shares of its common stock through March 24, 2028, in addition to the 12.95 million shares remaining under the prior authorizations, for an aggregate share buyback authorization of 22.95 million shares. As Cannae has previously announced, the Company has identified, as a strategic priority, the return of capital to shareholders through buybacks. The increased authorization demonstrates Cannae’s commitment to doing so. Buybacks may be made from time to time in the open market at prevailing prices, in privately negotiated transactions or through a tender offer. The repurchase program does not obligate the Company to acquire any specific number of shares over any particular time period and may be suspended or terminated at any time.

Cannae also announced its intention to migrate to annual election of directors on a phased basis. The Company will include a proposal regarding declassification of the Board at its 2025 annual shareholder meeting.

Mr. Foley added “The Board and I believe there remains significant embedded value in Cannae’s portfolio and upside in our stock price as we continue to execute on our strategic plan outlined when I returned as CEO. We recognize there is a significant net asset value discount in our stock price, and we are dedicated to minimizing that discount. We believe the monetization of DNB, our largest investment, coupled with the increased share buyback authorization, demonstrates our commitment to implementing our plan, returning capital to shareholders and driving an increase in our stock price. We also believe the declassification of our board demonstrates our continued practice of listening to and working with our shareholders.”

Forward-Looking Statements and Risk Factors

This press release contains forward-looking statements that involve a number of risks and uncertainties. Statements that are not historical facts, including statements regarding our expectations, hopes, beliefs, plans, intentions, or strategies regarding the future are forward-looking statements. Forward-looking statements are based on management’s beliefs, as well as assumptions made by, and information currently available to, management, including statements about the completion of the D&B transaction, our buyback program, board declassification, and our ability to implement our plans. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected. Except as required by applicable law, we undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The risks and uncertainties that forward-looking statements are subject to include, but are not limited to: risks associated with our ability to successfully operate businesses outside our traditional areas of focus; changes in general economic, business and political conditions, including changes in the financial markets and changes in macroeconomic conditions resulting from the outbreak of a pandemic or escalation of the current conflicts in Ukraine and the Middle East; risks associated with the Investment Company Act of 1940; risks associated with our potential inability to find suitable acquisition candidates, acquisitions in lines of business that will not necessarily be limited to our traditional areas of focus, or difficulties in integrating acquisitions; significant competition that our operating subsidiaries face; and risks related to the externalization of certain of our management functions to an external manager.

This press release should be read in conjunction with the risks detailed in the “Statement Regarding Forward-Looking Information,” “Risk Factors,” and other sections of the Company’s Forms 10-Q, Form 10-K and our other filings with the SEC.

Important Additional Information and Where to Find It

The Company intends to file a proxy statement on Schedule 14A, an accompanying WHITE proxy card, and other relevant documents with the SEC in connection with the solicitation of proxies from the Company’s shareholders for the Company’s 2025 annual meeting of shareholders. THE COMPANY’S SHAREHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE ACCOMPANYING WHITE PROXY CARD, AND ANY OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders may obtain a free copy of the definitive proxy statement, an accompanying WHITE proxy card, any amendments or supplements to the proxy statement, and other documents that the Company files with the SEC at no charge from the SEC’s website at www.sec.gov. Copies will also be available at no charge by clicking the “SEC Filings” link in the “Financials” section of the Company’s website at https://www.cannaeholdings.com/financial-information/sec-filings.

Certain Information Regarding Participants in the Solicitation

The Company, its directors (William P. Foley, II; Douglas K. Ammerman; Hugh R. Harris; C. Malcolm Holland; Mark D. Linehan; Frank R. Martire; Erika Meinhardt; Barry B. Moullet; James B. Stallings, Jr.; and Frank P. Willey) and certain of its executive officers (William P. Foley, II, Chief Executive Officer and Chief Investment Officer; Ryan R. Caswell, President; Bryan D. Coy, Chief Financial Officer; Peter T. Sadowski, Executive Vice President and Chief Legal Officer; and Michael L. Gravelle, Executive Vice President, General Counsel, and Corporate Secretary) and other employees may be deemed “participants” (as defined in Schedule 14A under the Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s shareholders in connection with the matters to be considered at the Company’s 2025 annual meeting of shareholders. Information regarding the names of the Company’s directors and executive officers and certain other individuals and their respective interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Compensation Discussion and Analysis and Executive and Director Compensation,” “Security Ownership of Certain Beneficial Owners, Directors and Executive Officers,” and “Executive Compensation” of the Company’s Proxy Statement on Schedule 14A in connection with the 2024 annual meeting of shareholders, filed with the SEC on April 26, 2024 (available here), and the Company’s Annual Report on Form 10-K, filed with the SEC on February 27, 2025 (available here). Supplemental information regarding the participants’ holdings of the Company’s securities can be found at no charge in SEC filings on Statements of Change in Ownership on Form 4 filed with the SEC on July 3, 2024 and February 28, 2025 for William P. Foley, II (available here and here); July 1, 2024, October 1, 2024, November 15, 2024 and January 3, 2025 for Douglas K. Ammerman (available here, here, here, and here); July 1, 2024, October 1, 2024, November 15, 2024 and January 3, 2025 for Hugh R. Harris (available here, here, here, and here); November 15, 2024 for C. Malcolm Holland (available here); November 15, 2024 for Mark D. Linehan (available here); July 1, 2024, October 1, 2024, November 15, 2024 and January 3, 2025 for Frank R. Martire (available here, here, here, and here); July 1, 2024, October 1, 2024, November 15, 2024 and January 3, 2025 for Erika Meinhardt (available here, here, here, and here); November 15, 2024 for Barry B. Moullet (available here); November 15, 2024 for James B. Stallings, Jr. (available here); November 15, 2024 for Frank P. Willey (available here); November 13, 2024, February 28, 2025 and March 21, 2025 for Michael L. Gravelle (available here, here and here); February 24, 2025, February 28, 2025, March 3, 2025 and March 17, 2025 for Peter T. Sadowski (available here, here, here and here); February 28, 2025, March 4, 2025 and March 17, 2025 for Ryan Caswell (available here, here and here); February 28, 2025, March 3, 2025 and March 17, 2025 for Bryan Coy (available here, here and here). Such filings are also available at no charge by clicking the “SEC Filings” link in the “Financials” section of the Company’s website at https://www.cannaeholdings.com/financial-information/sec-filings.

Any subsequent updates following the date hereof to the information regarding the identity of potential participants and their direct or indirect interests, by security holdings or otherwise, will be set forth in the Company’s proxy statement on Schedule 14A and other materials to be filed with the SEC in connection with the 2025 annual meeting of shareholders, if and when they become available. These documents will be available free of charge as described above.

About Cannae Holdings, Inc.

We primarily acquire interests in operating companies and are actively engaged in managing and operating a core group of those companies. We believe that our long-term ownership and active involvement in the management and operations of companies helps maximize the value of those businesses for our shareholders. We are a long-term owner that secures control and governance rights of other companies primarily to engage in their lines of business and we have no preset time constraints dictating when we sell or dispose of our businesses.

Jamie Lillis, Managing Director

Solebury Strategic Communications

203-428-3223

[email protected]

KEYWORDS: United States North America Nevada

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Super Hi Reports Unaudited Financial Results for the Fourth Quarter and Full Year 2024

SINGAPORE, March 25, 2025 (GLOBE NEWSWIRE) — Super Hi International Holding Ltd. (NASDAQ: HDL and HKEX: 9658) (“Super Hi” or the “Company”), a leading Chinese cuisine restaurant brand operating Haidilao hot pot restaurants in the international market, today announced its unaudited financial results for the three months (“Fourth Quarter 2024”) and the full year ended December 31, 2024 (“Full Year 2024”).

Fourth Quarter 2024 Highlights

  • Revenue was US$208.8 million, representing an increase of 10.4% from US$189.2 million in the same period of 2023.
  • In the fourth quarter of 2024, the Company opened 2 restaurants and simultaneously closed 1 restaurant to improve the restaurant configuration. The total number of Haidilao restaurants as of December 31, 2024 was 122, reflecting a net increase of 7 since December 31, 2023.
  • Total table turnover rate

    1
    was 3.9 times per day, and same-store table turnover rate2 was 4.0 times per day, both remaining stable compared to the same period of 2023.
  • Had over 8.0 million totalguest visits, representing an increase of 9.6% from 7.3 million in the same period of 2023. This growth was primarily attributable to restaurant network expansion and increased participation in group dining from the Company’s development of diverse group dining scenarios.
  • Same-store sales growth

    3
    was 4.2%.
  • Income from operation margin
    4 was 8.4%, compared to 6.4% in the same period of 2023.

Full Year 2024 Highlights

  • Revenue was US$778.3 million, representing an increase of 13.4% from US$686.4 million in the full year of 2023.
  • Total table turnover rate

    1
    was 3.8 times per day, compared to 3.5 times per day in the full year of 2023. Same-store table turnover rate2 was 3.9 times per day, compared to 3.6 times per day in the full year of 2023.
  • Had over 29.9 million totalguest visits, representing an increase of 12.0% from 26.7 million in the full year of 2023.
  • Same-store sales growth

    3
    was 7.1%.
  • Income from operation margin

    4
    was 6.8%, compared to 6.3% in the full year of 2023.

Ms. Yang Lijuan, CEO & Executive Director of Super Hi, commented, “This quarter, we continued to implement our strategy of ‘Dual focus on employee empowerment and customer-centric operations’ through various management tools, driving workforce productivity to provide customers with a pleasant dining experience. This quarter’s revenue increased by 10.4% year-over-year, while our income from operation margin4 improved by 2 percentage points compared to the same period of last year, mainly due to our focus on efficiency improvements, including supply chain optimization, enhanced restaurant management efficiency, and strengthened support and coordination between headquarters and stores.”

“In 2024, Super Hi continued to explore expansion in overseas markets, strengthening service capabilities for diverse customer segments. In 2024, Haidilao restaurants’ average overall table turnover rate was 3.8 times per day, an increase of 0.3 times per day from last year; Haidilao restaurant level operating margin improved by 1.1 percentage points year-over-year. Additionally, we launched the ‘Pomegranate plan’ in 2024. This strategic initiative draws inspiration from the pomegranate, where each seed represents a unique business form that collectively supports and forms our comprehensive catering service group. These efforts collectively drove a 13.4% year-over-year revenue growth for Super Hi in 2024, with the income from operation margin expanding by 0.5 percentage points during the same year.”

“Looking ahead, we remain committed to our strategic vision of becoming a leading global integrated restaurant group. While continuing to expand our Haidilao restaurant network and optimize our store layout, we will intensify support for the ‘Pomegranate plan’ to further diversify our business offerings and broaden our customer base.”

Fourth Quarter 2024 Financial Results

Revenue was US$208.8 million, representing an increase of 10.4% from US$189.2 million in the same period of 2023.

  • Revenue from Haidilao restaurant operations was US$199.9 million, representing an increase of 10.0% from US$181.7 million in the same period of 2023. The increase was mainly driven by (i) ongoing business expansion and increased brand influence; and (ii) continuous efforts to increase guest visits.
  • Revenue from delivery business was US$3.5 million, representing an increase of 12.9% from US$3.1 million in the same period of 2023, primarily due to (i) the expansion of the Company’s delivery network; and (ii) enhanced partnerships with local delivery platforms.
  • Revenue from other business was US$5.4 million, representing an increase of 22.7% from US$4.4 million in the same period of 2023, driven by (i) the increasing popularity of hot pot condiment products and Haidilao-branded and sub-branded food products among local customers and retailers; and (ii) the incubation of secondary branded restaurants under the Pomegranate plan through strategic exploration of diverse business forms.

Raw materials and consumables used were US$67.7 million, representing an increase of 2.9% from US$65.8 million in the same period of 2023. As a percentage of revenue, raw materials and consumables used decreased to 32.4% in the fourth quarter of 2024 from 34.8% in the same period of 2023. This decrease was primarily attributable to (i) enlargement of business scale driven by revenue increase; and (ii) the optimization of the Company’s procurement costs.

Staff costs were US$67.2 million, representing an increase of 9.6% from US$61.3 million in the same period of 2023. The increase was primarily due to (i) an increase in the number of employees in line with restaurant network expansion compared to the same period of 2023, along with an increase in guest visits and table turnover rate; and (ii) the Company’s operational strategy of ensuring a sufficient number of employees to provide superior customer experience in catering services, product quality, restaurant environment and food safety. As a percentage of revenue, staff costs remained relatively stable at 32.2% in the fourth quarter of 2024, compared to 32.4% in the fourth quarter of 2023.

Income from operation

5
was US$17.5 million, representing an increase of 44.6% from US$12.1 million in the same period of 2023. Income from operation margin4 was 8.4%, compared to 6.4% in the same period of 2023. This increase in income from operations was mainly attributable to (i) an increase in revenue and table turnover rate as described above; and (ii) an improvement in operational efficiency, especially through the optimization of the global supply chain and enhanced cost control.

Loss for the period was US$11.6 million, compared to a profit of US$23.3 million in the same period of 2023. This change was mainly due to an increase in net foreign exchange loss of US$40.4 million, primarily attributable to foreign exchange fluctuations, particularly the depreciation of local currencies against the U.S. dollar, which is partially offset by (i) an increase in revenue driven by ongoing business expansion and continuous efforts in increasing guest visits and table turnover rate; and (ii) an improvement in operational efficiency.

Basic and diluted
net loss per sha
re were both US$0.02, compared to a basic and diluted net profit per share of US$0.04 in the same period of 2023.

Full Year 2024 Financial Results

Revenue was US$778.3 million, representing an increase of 13.4% from US$686.4 million in the full year of 2023.

  • Revenue from Haidilao restaurant operations was US$747.3 million, representing an increase of 13.0% from US$661.2 million in the full year of 2023. The increase was mainly driven by (i) the enhanced Haidilao restaurant operations driven by improved table turnover rates and customer traffic growth through the Company’s continuous efforts; and (ii) the continued strategic expansion of its business network throughout 2024.
  • Revenue from delivery business was US$11.3 million, representing an increase of 15.3% from US$9.8 million in the full year of 2023, primarily due to (i) the growth of the Company’s brand influence; and (ii) its continuous efforts in promoting its food delivery services by collaborating with local food delivery platforms.
  • Revenue from other business was US$19.7 million, representing an increase of 27.9% from US$15.4 million in the full year of 2023, driven by (i) the increasing popularity of hot pot condiment products and Haidilao-branded and sub-branded food products among local customers and retailers; and (ii) the incubation of secondary branded restaurants through the strategic exploration of diverse business forms.

Raw materials and consumables used were US$257.7 million, representing an increase of 9.8% from US$234.7 million in the full year of 2023. As a percentage of revenue, raw materials and consumables used decreased to 33.1% in the full year of 2024 from 34.2% in the full year of 2023. This decrease was primarily attributable to (i) enlargement of business scale driven by revenue increase; (ii) the optimization of the Group’s procurement costs; and (iii) the enhancement of its restaurant management strategies, including the development of localized supply chains tailored to restaurant operations.

Staff costs were US$259.3 million, representing an increase of 14.7% from US$226.0 million in the full year of 2023. The increase was primarily due to the increase in the number of employees, which was in line with (i) the expansion of the restaurant network; (ii) the increase in guest visits and table turnover rate; and (iii) our operation strategy of ensuring sufficient number of employees to provide superior customer experience in catering services, product quality, restaurant environment and food safety, as well as the increase in statutory minimum wages in certain countries where we operated. As a percentage of revenue, the Group’s staff costs increased from 32.9% in 2023 to 33.3% in 2024.

Income from operation

5
was US$53.3 million, representing an increase of 23.7% from US$43.1 million in the full year of 2023. Income from operation margin4 was 6.8%, compared to 6.3% in the full year of 2023. This increase in income from operations was mainly attributable to an increase in the Group’s revenue with economies of scale driving optimization of operating expenses, as well as an improvement in gross profit margin driven by supply chain optimization.

Profit for the year was US$21.4 million, representing a decrease of 15.4% from US$25.3 million in 2023. This change was primarily due to the increase in net foreign exchange loss of US$14.7 million, driven mainly by foreign exchange fluctuations, particularly the depreciation of local currencies against the U.S. dollar, which is partially offset by (ii) an increase in revenue driven by ongoing business expansion and continuous efforts in increasing guest visits and table turnover rate; and (iii) an improvement in operational efficiency.

Basic and diluted
net profit per sha
re were both US$0.04, compared to US$0.05 in the full year of 2023.

Non-IFRS Financial Measure

In evaluating the Group’s business, the Group considers and uses a non-IFRS measure, restaurant level operating profit margin, which is calculated by dividing (i) restaurant level operating profit by (ii) restaurant level revenue, as supplemental measures to review and assess its operating performance. The presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS Accounting Standards.

Restaurant level operating profit margin is a supplemental measure of operating performance of the Group’s restaurants and its calculations thereof may not be comparable to similar measures reported by other companies. Restaurant level operating profit margin has limitations as an analytical tool and should not be considered as a substitute for analysis of the Group’s results as reported under IFRS Accounting Standards.

Restaurant level revenue refers to the total revenue generated from the Group’s two major service lines – Haidilao restaurant operations and delivery business.

Restaurant level operating profit is calculated by deducting from restaurant level revenue certain restaurant level costs and expenses, including (i) restaurant level expenses, including cost of restaurant level raw materials and consumables used, restaurant level staff costs, restaurant level property rentals and related expenses, restaurant level utilities expenses, restaurant level depreciation and amortization, restaurant level traveling and communication expenses and other restaurant level expenses, including preopening expenses in each region; and (ii) management fees incurred in each region. The cost of restaurant level raw materials and consumables used included the cost of food ingredients and consumables associated with central kitchens that are used within the Group’s Haidilao restaurants as well as those procured directly from suppliers.

The Group believes that restaurant level operating profit margin is an important measure to evaluate the performance and profitability of each of the Group’s restaurants, individually and in the aggregate. The Group uses restaurant level operating profit margin information to benchmark the Group’s performance versus competitors.

The table set forth below reconciles total revenue to restaurant level revenue:

  For the Year ended December 31,
  2024 2023
  USD’000 USD’000
Total revenue 778,308 686,362
Less: Revenue (Others) (19,719) (15,393)
Restaurant level revenue 758,589 670,969
 

The computation of restaurant level operating margin is as follows:

  For the Year ended December 31,
  2024 2023
  USD’000 USD’000
Restaurant level revenue 758,589 670,969
Less: Restaurant level costs and expenses (682,075) (610,695)
Restaurant level operating profit 76,514 60,274
Restaurant level operating margin* 10.1% 9.0%
     

*   Restaurant level operating margin is calculated by dividing (i) restaurant level operating profit by (ii) restaurant level revenue.

The table set forth below reconciles income from operation, the most directly comparable IFRS measure to the restaurant level operating profit.

  For the Year ended December 31,
  2024 2023
  USD’000 USD’000
Income from operation(1) 53,311 43,121
Less:    
Revenue (Others) (19,719) (15,393)
Other income(2) (2,449) (4,849)
Add non-restaurant level cost and expenses(3):    
Raw materials and consumables used(4) 10,343 8,021
Staff costs 10,992 10,349
Rentals and related expenses 989 730
Utilities expenses 1,783 1,431
Depreciation and amortization 6,353 7,864
Traveling and communication expenses 995 768
Listing expenses 2,460 1,745
Other expenses 10,136 11,100
Other gains (losses) – net(5) 1,320 (4,613)
Restaurant level operating profit 76,514 60,274
Restaurant level operating margin 10.1% 9.0%
 

Notes:
(1) Income from operation is calculated by profit for the year excluding interest income (included within other income), finance costs, unrealized foreign exchange differences arising from remeasurement of balances which are not denominated in functional currency, net gain arising on financial assets at FVTPL and income tax expense.

(2) Other income primarily consists of the subsidies received from the local governments for the Group’s business development but does not include non-operating interest income.

(3) Non-restaurant level cost and expenses mainly relate to costs associated with Revenue (Others), operational costs and expenses associated with central kitchens, and corporate and unallocated costs.

(4) Raw materials and consumables used in non-restaurant level operations mainly relate to cost of food ingredients purchased by central kitchens that are not used for Haidilao restaurants, but which are used for sales of hot pot condiment products and food under Haidilao brand and secondary brands to local guests and retailers.

(5) Other gains (losses) – net primarily consist of net impairment (loss) reversal recognized in respect of property, plant and equipment and right-of-use assets, but do not include unrealized foreign exchange differences arising from remeasurement of balances which are not denominated in functional currency and net gain arising on financial assets at FVTPL.

Operational Highlights

Haidilao Restaurant Performance

The following table summarizes key performance indicators of Haidilao’s restaurants for the periods indicated.

  As of December 31,
  2024   2023
Number of restaurants      
Southeast Asia 73   70
East Asia 19   17
North America 20   18
Others(1) 10   10
Total 122   115
       

 

  For the Three Months Ended

December 31,
For the Year Ended

December 31,
  2024   2023   2024   2023
               
Total guest visits
(million)
             
Southeast Asia 5.4   5.0   20.7   18.8
East Asia 0.9   0.8   3.3   2.9
North America 1.1   0.9   3.7   3.0
Others(1) 0.6   0.6   2.2   2.0
Overall 8.0   7.3   29.9   26.7
               
Table turnover rate

(2)

(times per day)
             
Southeast Asia 3.7   3.8   3.7   3.5
East Asia 4.8   4.1   4.4   3.6
North America 4.2   4.3   4.1   3.7
Others(1) 4.2   4.1   3.9   3.8
Overall 3.9   3.9   3.8   3.5

Average spending per guest

(3)

(US$)

             
Southeast Asia 19.5   19.1   19.6   19.5
East Asia 28.4   28.2   28.3   27.8
North America 41.0   43.6   42.3   45.3
Others(1) 39.3   40.9   41.6   40.2
Overall 25.0   24.7   25.0   24.8

 

Average daily revenue per restaurant

(4)

(US$ in thousands)
             
Southeast Asia 16.0   15.6   15.7   15.0
East Asia 19.2   15.3   17.1   12.9
North America 24.3   23.1   22.0   20.4
Others(1) 26.1   25.5   24.9   23.6
Overall 18.7   17.7   17.7   16.3
               

Notes:
(1) Others include Australia, the United Kingdom, and the United Arab Emirates.

(2) Calculated by dividing total number of tables served for the years/periods by the product of total Haidilao restaurant operation days for the year/period and average table count during the year/period in the same geographic region.

(3) Calculated by dividing gross revenue of Haidilao restaurant operation for the years/periods by total guests served for the years/periods in the same geographic region.

(4) Calculated by dividing the revenue of Haidilao restaurant operation for the years/periods by the total Haidilao restaurant operation days of the periods in the same geographic region.

Same-Store Sales

The following table sets forth details of the Company’s same store sales for the periods indicated.

  As of/For the Three Months Ended December 31, As of/For the Year Ended December 31,
  2024   2023   2024   2023
Number of Same Stores

(1)
             
Southeast Asia 63 60
East Asia 14 13
North America 18 18
Others(5) 10 7
Total 105 98
               
Same Store Sales

(2)

(US$ in thousands)
             
Southeast Asia 95,717   94,391   360,213   348,237
East Asia 24,636   20,908   79,970   65,545
North America 40,619   38,638   147,834   135,311
Others(5) 24,029   23,559   65,974   61,599
Total 185,001   177,496   653,991   610,692
               
Average same store sales per day

(3)

(US$ in thousands)
             
Southeast Asia 16.5   16.3   16.4   16.0
East Asia 19.1   16.2   16.8   13.9
North America 24.5   23.3   22.4   20.6
Others(5) 26.2   25.7   26.1   24.4
Total 19.2   18.4   18.3   17.1
               
Average same store table turnover rate

(4)

(times/day)
             
Southeast Asia 3.8   3.9   3.8   3.6
East Asia 4.8   4.3   4.3   3.6
North America 4.2   4.3   4.1   3.7
Others(5) 4.2   4.1   3.9   3.7
Total 4.0   4.0   3.9   3.6
               

Notes:

(1) Includes restaurants that commenced operations prior to the beginning of the years/periods under comparison and opened for more than 75 days in the fourth quarter and opened for more than 300 days in the full year of 2023 and 2024, respectively.

(2) Refers to the aggregate gross revenue from Haidilao restaurant operation at the Company’s same stores for the years/periods indicated.

(3) Calculated by dividing the gross revenue from Haidilao restaurant operation for the years/periods by the total Haidilao restaurant operation days at the Company’s same stores for the years/periods.

(4) Calculated by dividing the total tables served for the years/periods by the product of total Haidilao restaurant operation days for the period and average table count at the Company’s same stores during the years/periods.

(5) Others include Australia, the United Kingdom, and the United Arab Emirates.

About Super Hi

Super Hi operates Haidilao hot pot restaurants in the international market. Haidilao is a leading Chinese cuisine restaurant brand. With roots in Sichuan from 1994, Haidilao has become one of the most popular and largest Chinese cuisine brands in the world. With over 30 years of brand history, Haidilao is well-loved by guests for its unique dining experience — warm and attentive service, great ambiance and delicious food, standing out among global restaurant chains, which has made Haidilao restaurants into a worldwide cultural phenomenon. Haidilao has been ranked as one of the world’s most valuable restaurant brands for six consecutive years since 2019, earning the title of “World’s Strongest Restaurant Brand” for 2024 (Brand Finance). As of December 31, 2024, Super Hi had 122 self-operated Haidilao restaurants in 14 countries across four continents, making it the largest Chinese cuisine restaurant brand in the international market in terms of number of countries covered by self-operated restaurants.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking” statements pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Super Hi may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the “SEC”), in its annual report to shareholders, in announcements, circulars or other publications made on the website of The Stock Exchange of Hong Kong Limited (the “SEHK”), in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Super Hi’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Super Hi’s operations and business prospects; future developments, trends and conditions in the industry and markets in which Super Hi operates; Super Hi’s strategies, plans, objectives and goals and Super Hi’s ability to successfully implement these strategies, plans, objectives and goals; Super Hi’s ability to maintain an effective food safety and quality control system; Super Hi’s ability to continue to maintain its leadership position in the industry and markets in which Super Hi operates; Super Hi’s dividend policy; Super Hi’s capital expenditure plans; Super Hi’s expansion plans; Super Hi’s future debt levels and capital needs; Super Hi’s expectations regarding the effectiveness of its marketing initiatives and the relationship with third-party partners; Super Hi’s ability to recruit and retain qualified personnel; relevant government policies and regulations relating to Super Hi’s industry; Super Hi’s ability to protect its systems and infrastructures from cyber-attacks; general economic and business conditions globally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in Super Hi’s filings with the SEC and the announcements and filings on the website of the SEHK. All information provided in this press release is as of the date of this press release, and Super Hi does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Contacts

Investor Relations
Email: [email protected]
Phone: +1 (212) 574-7992

Public Relations
Email: [email protected]

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

  For the three months ended December 31, For the years ended December 31,
  2024 2023 2024 2023
  USD’000 USD’000 USD’000 USD’000
         
         
Revenue 208,762   189,179   778,308   686,362  
Other income 2,167   851   7,523   6,695  
Raw materials and consumables used (67,684 ) (65,774 ) (257,723 ) (234,715 )
Staff costs (67,171 ) (61,262 ) (259,293 ) (226,033 )
Rentals and related expenses (5,661 ) (5,547 ) (20,136 ) (17,161 )
Utilities expenses (7,131 ) (6,716 ) (28,358 ) (26,054 )
Depreciation and amortization (21,572 ) (18,994 ) (80,972 ) (78,557 )
Travelling and communication expenses (1,723 ) (1,897 ) (6,449 ) (5,756 )
Listing expenses   (1,745 ) (2,460 ) (1,745 )
Other expenses (20,488 ) (18,108 ) (70,735 ) (62,682 )
Other gains and losses – net (25,656 ) 17,714   (17,924 ) 1,177  
Finance costs (2,448 ) (2,268 ) (8,538 ) (8,424 )
(Loss) Profit before tax (8,605 ) 25,433   33,243   33,107  
Income tax expense (3,003 ) (2,164 ) (11,844 ) (7,850 )
(Loss) Profit for the period/year (11,608 ) 23,269   21,399   25,257  
         
Other comprehensive income (expense)        

Item that may be reclassified subsequently



to profit or loss:
       
Exchange differences arising on translation of

foreign operations

12,362   (9,961 ) 12,028   4,627  
Total comprehensive income

for the period/year
754   13,308   33,427   29,884  
         
(Loss) Profit for the period/year attributable to:        
Owners of the Company (11,340 ) 23,506   21,801   25,653  
Non-controlling interests (268 ) (237 ) (402 ) (396 )
  (11,608 ) 23,269   21,399   25,257  
         
Total comprehensive income

attributable to:
       
Owners of the Company 1,022   13,545   33,829   30,280  
Non-controlling interests (268 ) (237 ) (402 ) (396 )
  754   13,308   33,427   29,884  
         
(Loss) Earnings per share        
Basic and diluted (USD) (0.02 ) 0.04   0.04   0.05  
       
       

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

  As at December 31, As at December 31,
  2024 2023
  USD’000 USD’000
     
Non-current Assets    
Property, plant and equipment 151,901 168,724
Right-of-use assets 185,514 167,641
Intangible assets 278 402
Deferred tax assets 3,799 1,995
Other receivables 1,961 1,961
Prepayment 373 295
Rental and other deposits 17,372 16,903
  361,198 357,921
     
Current Assets    
Inventories 31,521 29,762
Trade and other receivables and prepayments 30,754 29,324
Rental and other deposits 3,378 3,882
Pledged bank deposits 2,855 3,086
Bank balances and cash 254,719 152,908
  323,227 218,962
     
Current Liabilities    
Trade payables 30,711 34,375
Other payables 38,100 34,887
Amounts due to related parties 1,329 842
Tax payable 5,411 9,556
Lease liabilities 41,407 38,998
Contract liabilities 9,669 8,306
Provisions 1,941 1,607
  128,568 128,571
     
Net Current Assets 194,659 90,391
     


UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

  As at December 31, As at December 31,
  2024 2023
  USD’000 USD’000
     
Non-current Liabilities    
Deferred tax liabilities 7,504   1,347  
Lease liabilities 171,219   163,947  
Contract liabilities 2,980   3,098  
Provisions 12,493   7,799  
  194,196   176,191  
     
Net Assets 361,661   272,121  
     
     
Capital and Reserves    
Share capital 3   3  
Shares held under share award scheme *   *  
Share premium 550,593   494,480  
Reserves (190,568 ) (224,397 )
Equity attributable to owners of the Company 360,028   270,086  
Non-controlling interests 1,633   2,035  
Total Equity 361,661   272,121  
     
     

*     Less than USD1,000

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

  For the three months ended
December 31,
For the years ended

December 31,
  2024 2023 2024 2023
  USD’000 USD’000 USD’000 USD’000
       
Net cash from operating activities 30,995   30,391   119,696   114,045  
Net cash from (used in) investing activities 23,347   57,277   (27,616 ) (11,775 )
Net cash (used in) from financing activities (8,813 ) (10,823 ) 12,577   (43,787 )
Net increase in cash and cash equivalents 45,529   76,845   104,657   58,483  
Cash and cash equivalents at beginning of the period/year 215,162   75,271   152,908   93,878  
Effect of foreign exchange rate changes (5,972 ) 792   (2,846 ) 547  
Cash and cash equivalents at end of the period/year 254,719   152,908   254,719   152,908  
 

______________________
1
Calculated by dividing the total tables served for the year/period by the product of total Haidilao restaurant operation days for the year/period and average table count during the year/period.
2 Calculated by dividing the total tables served for the years/periods by the product of total Haidilao restaurant operation days for the year/period and average table count at the Company’s same stores during the years/periods.
3 Refers to the year-over-year growth of the aggregate gross revenue from Haidilao restaurant operations at the Company’s same stores for the year/period indicated.
4 Calculated by dividing income from operation5 by total revenue.
5 Calculated by excluding interest income, finance costs, unrealized foreign exchange differences arising from remeasurement of balances which are not denominated in functional currency, net gain arising on financial assets at fair value through profit or loss and income tax expense from profit (loss) for the year/period.



Datavault AI Licenses Patented ADIO Technology to NYIAX, Ushering in a New Era of Ultrasonic Advertising

Datavault AI Licenses Patented ADIO Technology to NYIAX, Ushering in a New Era of Ultrasonic Advertising

Licensing Deal Strengthens Focus on Information Data Exchange While Introducing a Privacy-First Advertising Category

BEAVERTON, Ore.–(BUSINESS WIRE)–
Datavault AI Inc. (Nasdaq: DVLT), a leader in AI-driven data valuation and monetization, today announced a strategic licensing agreement with NYIAX, the Nasdaq-powered trading platform. This agreement integrates Datavault AI’s patented ADIO® technology into NYIAX’s cutting-edge advertising exchange, creating one of the world’s first fully functional ultrasonic advertising platforms. Technical integration is expected to be completed in Q2 2025, with combined product offerings available for customer deployments in 2H 2025.

This pioneering collaboration leverages ADIO’s unique capability to deliver data over sound, introducing a novel advertising category that seamlessly engages both venue-based and broadcast audiences. By embedding inaudible data within audio streams, ADIO-powered advertisements reach consumers in stadiums, theaters, retail spaces, and across broadcast networks, all while maintaining strict privacy protections.

Revolutionizing Digital Advertising with Privacy-First Innovation

“This agreement with NYIAX strengthens our core mission of expanding the Information Data Exchange® (IDE) while simultaneously introducing a transformative, licensing-based revenue stream for Datavault AI,” said Nathaniel Bradley, CEO of Datavault AI. “By entrusting NYIAX with the commercialization of ADIO technology, we empower advertisers to tap into a medium that seamlessly bridges digital and physical experiences, offering unparalleled reach, security, and efficiency.”

Through this exclusive licensing deal, Datavault AI provides NYIAX with cyber-secure, patent-protected ADIO technology, enabling advertisers to purchase ultrasonic ad inventory as easily as traditional digital formats. Integrated with NYIAX’s blockchain-backed platform, ADIO represents a paradigm shift away from outdated cookie-based advertising models. Instead, it prioritizes consumer privacy, autonomy and security by eliminating intrusive tracking methods and delivering targeted content through sound.

The integration of ADIO into NYIAX’s platform provides advertisers with a frictionless way to list, price, and trade ultrasonic ad inventory with the same efficiency and transparency as other media assets. For brands, ADIO delivers a game-changing opportunity to connect with consumers in real-time, in highly targeted environments, without compromising privacy.

“Authenticated scalability and direct consumer engagement are no longer optional for brands seeking competitive differentiation,” said Joseph Stonbely II, Founder & Executive Producer of Mission: IGNITION (inc.) “We’ve long considered the NYIAX platform our most essential front-line resource for delivering meaningful, value-engineered brand experiences with partners like Marriott Bonvoy and LVMH. The addition of Datavault AI now brings full-circle capabilities to engage consumers with relevance and impact — in-venue, on-site, and in the critical real-time moment.”

This next-generation solution is further strengthened by Datavault AI’s suite of AI-driven financial analytics tools—DataScore®, DataValue®, and DataBank®—which provide real-time pricing, valuation, and liquidity management, ensuring secure transactions within an immutable blockchain environment.

“We’re thrilled to be collaborating on an exclusive basis with Datavault AI to scale ADIO — introducing another future-forward advertising and customer engagement solution to the industry,” said Teri Gallo, CEO of NYIAX. “As brands seek deeper, more personalized connections with consumers, ADIO delivers a powerful new channel for promotions, brand messaging, and infotainment—right in the moment of opportunity. For venues, it unlocks fresh revenue streams while transforming how they engage their audiences. This is an incredibly transformative and additive layer to the broader investments marketers are already making in retail media and omnichannel strategies. It’s just the beginning of what NYIAX is bringing to the future of media and marketing.”

Mission: IGNITION (Inc)

With over $285 million in certified media billings and brokerage, Mission: IGNITION (inc.) delivers non-traditional media campaign management, live event and spectacle conceptualization, and digital media display restructuring. All services are fully executed by our award-winning in-house team, operating out of Times Square, Englewood Cliffs, and Las Vegas. Specializing in launching new brands into market, Mission: IGNITION provides an impact agency model—offering customized success mapping for multinational corporations, major ad firms, independent businesses, and startups. In select cases, Mission: IGNITION also acts as a strategic financial investor. Founded in 2021, Mission: IGNITION is the legacy entity to TSQ Worldwide, which was wholly acquired by Peter Holt in 2017.

About Datavault AI Inc.

Datavault AI1 (Nasdaq: DVLT) is leading the way in AI experience, valuation and monetization of assets in the Web 3.0 environment. The company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The company is headquartered in Beaverton, OR. Learn more about Datavault AI at www.dvlt.ai.

About NYIAX

NYIAX operates a NASDAQ-integrated trading platform that enables trading of long-term media contracts. Using patented blockchain-powered technology, the platform brings financial market standards to advertising transactions, improving transparency and automation.

Built on the NASDAQ Financial Framework, NYIAX provides an exchange where advertisers and media owners negotiate, secure and reconcile future advertising contracts with the efficiency and compliance of financial instruments. Learn more here.

Cautionary Note Regarding Forward-Looking Statements

This press release of Datavault AI contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, include, among others, the Company’s expectations with respect to the strategic business and intellectual property agreements (the “Agreements”), including statements regarding the benefits of the Agreements, the implied valuation of the Company, the products offered by the Company and the markets in which it operates, and the Company’s projected future results and market opportunities, as well as information with respect to Datavault AI’s future operating results and business strategy. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of a variety of factors, including, but not limited to: (i) risks and uncertainties impacting Datavault AI’s business including, risks related to its current liquidity position and the need to obtain additional financing to support ongoing operations, Datavault AI’s ability to continue as a going concern, Datavault AI’s ability to maintain the listing of its common stock on Nasdaq, Datavault AI’s ability to predict the timing of design wins entering production and the potential future revenue associated with design wins, Datavault AI’s ability to predict its rate of growth, Datavault AI’s ability to predict customer demand for existing and future products and to secure adequate manufacturing capacity, consumer demand conditions affecting Datavault AI’s customers’ end markets, Datavault AI’s ability to hire, retain and motivate employees, the effects of competition on Datavault AI’s business, including price competition, technological, regulatory and legal developments, developments in the economy and financial markets, and potential harm caused by software defects, computer viruses and development delays, (ii) risks related to Datavault AI’s ability to realize some or all of the anticipated benefits from the Agreements, any risks that may adversely affect the business, financial condition and results of operations of Datavault AI after the completion of the Agreements, including but not limited to cybersecurity risks, the potential for AI design and usage errors, risks related to regulatory compliance and costs, potential harm caused by data privacy breaches, digital business interruption and geopolitical risks, and (iii) other risks as set forth from time to time in Datavault AI’s filings with the U.S. Securities and Exchange Commission. The information in this press release is as of the date hereof and the Company undertakes no obligation to update such information unless required to do so by law. The reader is cautioned not to place under reliance on forward looking statements. The Company does not give any assurance that the Company will achieve its expectations.

1 Formerly known as WiSA Technologies, Inc.

Investor and Media Contacts

Investors:

David Barnard, Alliance Advisors Investor Relations

(415) 433-3777

[email protected]

Media Inquiries:

Sonia Choi

(844) DATA-400

[email protected]

KEYWORDS: United States North America Oregon

INDUSTRY KEYWORDS: Mobile/Wireless Technology Other Technology Software Audio/Video Hardware Data Management Consumer Electronics Artificial Intelligence Web3

MEDIA:

Logo
Logo

Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results

GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported unaudited financial results for the three months and the year ended December 31, 2024.

2024 Business Overview and Recent Updates

  • Corporate Updates

    • Completed profitability-driven organizational optimization, execution towards profitability well underway
  • Early Detection  

    • THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection and origin prediction.
  • Therapy Selection

    • Presented study results on small-cell lung cancer and colorectal cancer at the ASCO in June 2024. “The efficacy and safety of high dose Almonertinib in untreated EGFR-mutated NSCLC with brain metastases, including biomarker analysis” and “Individualized tumor-informed circulating tumor DNA analysis for molecular residual disease detection in predicting recurrence and efficacy of adjuvant chemotherapy in colorectal cancer.”
    • Presented study results at the 2024 World Conference on Lung Cancer in September 2024. “Neoadjuvant sintilimab plus chemotherapy could be an optional treatment modality in selected EGFR-mutant NSCLC” and “Distinct Genomic and Immune Microenvironment Features of Solid or Micropapillary Predominant Subtype in Stage I Lung Adenocarcinomas.”
  • Pharma Services

    • New companion diagnostics (CDx) collaboration announced with Bayer in China in May 2024.
    • The companion diagnostic (CDx) for EGFR exon 20 insertion mutation (exon20ins) for sunvozertinib, developed through the collaboration of Burning Rock and Dizal, has been approved by the National Medical Products Administration (NMPA) of China in October 2024, which marks the first co-developed NGS-based CDx for lung cancer approved by NMPA since the release of the CDx guideline in China.

Fourth Quarter 2024 Financial Results

Revenues were RMB126.0 million (US$17.3 million) for the three months ended December 31, 2024, representing a 4.1% increase from RMB121.1 million for the same period in 2023.

  • Revenue generated from central laboratory business was RMB39.3 million (US$5.4 million) for the three months ended December 31, 2024, representing a 23.4% decrease from RMB51.3 million for the same period in 2023, primarily attributable to a decrease in the number of tests, as we continued our transition towards in-hospital testing.
  • Revenue generated from in-hospital business was RMB43.5 million (US$6.0 million) for the three months ended December 31, 2024, representing a 50.9% increase from RMB28.8 million for the same period in 2024, driven by an increase in sales volume from existing hospitals and new contracted partner hospitals.
  • Revenue generated from pharma research and development services was RMB43.3 million (US$5.9 million) for the three months ended December 31, 2024, representing a 5.6% increase from RMB41.0 million for the same period in 2023, primarily attributable to increased development and testing services performed for our pharma customers.

Cost of revenues was RMB36.6 million (US$5.0 million) for the three months ended December 31, 2024, representing a 14.8% decrease from RMB43.0 million for the same period in 2023, primarily due to (i) a decrease in cost of central laboratory business, which was in line with the decrease in revenue generated from this business; and (ii) a decrease in amortization expense for all kinds of business.

Gross profit was RMB89.4 million (US$12.3 million) for the three months ended December 31, 2024, representing a 14.5% increase from RMB78.1 million for the same period in 2023. Gross margin was 71.0% for the three months ended December 31, 2024, compared to 64.5% for the same period in 2023. By channel, gross margin of central laboratory business was 84.4% for the three months ended December 31, 2024, compared to 81.7% during the same period in 2023, primarily due to the decreased depreciation; gross margin of in-hospital business was 68.0% for the three months ended December 31, 2024, compared to 44.8% during the same period in 2023, and such increase was primarily due to an increase in sales volume to high margin hospitals and decreased depreciation and rental cost in relation to our laboratory of Guangzhou headquarters; gross margin of pharma research and development services was 61.7% for the three months ended December 31, 2024, compared to 56.9% during the same period of 2023, primarily due to an increase in test volume of higher margin projects.

Non-GAAP gross profit, which excludes depreciation and amortization expenses, was RMB93.6 million (US$12.8 million) for the three months ended December 31, 2024, representing a 7.5% increase from RMB87.1 million for the same period in 2023. Non-GAAP gross margin was 74.3% for the three months ended December 31, 2024, compared to 71.9% for the same period in 2023. For more details on these non-GAAP financial measures, please see the table captioned “Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Operating expenses were RMB171.3 million (US$23.5 million) for the three months ended December 31, 2024, representing a 29.9% decrease from RMB244.4 million for the same period in 2023. The decrease was primarily driven by budget control measures, including headcount reduction, to improve our operating efficiency.

  • Research and development expenses were RMB52.2 million (US$7.2 million) for the three months ended December 31, 2024, representing a 28.6% decrease from RMB73.1 million for the same period in 2023, primarily due to (i) a decrease in the expenditure for detection research, and (ii) a decrease in amortized expense on share-based compensation; and (iii) a decrease in amortized expenses for office building decoration.
  • Selling and marketing expenses were RMB46.7 million (US$6.4 million) for the three months ended December 31, 2024, representing a 6.1% decrease from RMB49.8 million for the same period in 2023, primarily due to a decrease in staff cost resulted from the reorganization of our sales department to improve operating efficiency.
  • General and administrative expenses were RMB37.3 million (US$5.1 million) for the three months ended December 31, 2024, representing a 69.3% decrease from RMB121.5 million for the same period in 2023, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in amortized expenses for office building decoration; and (iii) a decrease in impairment expenses for accounts receivables and contract assets resulting from accelerated settlement with customers with long accounts receivable.

Net loss was RMB81.3 million (US$11.1 million) for the three months ended December 31, 2024, compared to RMB162.2 million for the same period in 2023.

Cash, cash equivalents, restricted cash were RMB522.2 million (US$71.5 million) as of December 31, 2024.

Full Year 2024 Financial Results

Revenues were RMB515.8 million (US$70.7 million) for 2024, representing a 4.0% decrease from RMB537.4 million for 2023.

  • Revenue generated from central laboratory business was RMB175.6 million (US$24.1 million) for 2024, representing a 24.6% decrease from RMB232.8 million for 2023, primarily attributable to a decrease in the number of tests, as we continued our transition towards in-hospital testing.
  • Revenue generated from in-hospital business was RMB224.5 million (US$30.8 million) for 2024, representing an 19.0% increase from RMB188.7 million for 2023, driven by an increase in sales volume from existing hospitals and new contracted partner hospitals.
  • Revenue generated from pharma research and development services was RMB115.7 million (US$15.8 million) for 2024, remaining relatively stable (decreasing by 0.2%) from RMB115.9 million for 2023.

Cost of revenues was RMB153.4 million (US$21.0 million) for 2024, representing a 11.9% decrease from RMB174.2 million for 2023, primarily due to a decrease in cost of revenues for our central laboratory business, as we continued our transition towards in-hospital testing.

Gross profit remained relatively stable at RMB362.4 million (US$49.6 million) for 2024, compared to RMB363.2 million for the same period in 2023. Gross margin increased to 70.3% for 2024 from 67.6% for 2023.

Non-GAAP gross profit, which excludes depreciation and amortization expenses, was RMB386.3 million (US$52.9 million) for 2024, representing a 3.3% decrease from RMB399.4 million for 2023. Non-GAAP gross margin was 74.9% for 2024, compared to 74.3% for 2023. For more details on these non-GAAP financial measures, please see the table captioned “Reconciliations of GAAP and Non-GAAP Results” set forth at the end of this press release.

Operating expenses were RMB720.0 million (US$98.6 million) for 2024, representing a 30.3% decrease from RMB1,032.5 million for 2023.

  • Research and development expenses were RMB232.3 million (US$31.8 million) for 2024, representing a 33.1% decrease from RMB347.0 million for 2023, primarily due to (i) a decrease in the expenditure for detection research; (ii) a decrease in amortized expense on share-based compensation; (iii) a decrease in staff cost resulted from the reorganization of our research and development department to improve operating efficiency; and (iv) a decrease in amortized expenses for office building.
  • Selling and marketing expenses were RMB190.9 million (US$26.2 million) for 2024, representing a 22.9% decrease from RMB247.7 million for 2023, primarily due to (i) a decrease in staff cost resulted from the reorganization of our sales department to improve operating efficiency; (ii) a decrease in marketing and conference fee; (iii) a decrease in amortized expense on share-based compensation; and (iv) a decrease in travel expense.
  • General and administrative expenses were RMB261.6 million (US$35.8 million) for 2024, representing a 40.2% decrease from RMB437.8 million for 2023, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in amortized expenses for office building; (iii) a decrease in staff cost resulted from the reorganization of our general and administrative department to improve operating efficiency; and (iv) a decrease in operating lease.
  • Impairment loss on long-lived assets were RMB35.1 million (US$4.8 million) for the year ended December 31, 2024 as a result of the long-lived assets impairment test conducted by the management.

Net loss was RMB346.6 million (US$47.5 million) for 2024, compared to RMB653.7 million for 2023.

Exchange Rate Information

This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB7.2993 to US$1.00, the exchange rate on December 31, 2024, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Non-GAAP Measures

In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance and formulate business plans. However, the presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). These non-GAAP financial measures may be different from non-GAAP methods of accounting and reporting used by other companies, including peer companies, and therefore their comparability may be limited.

The Company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The Company defines non-GAAP gross margin as non-GAAP gross profit divided by its revenue.

The Company believes presenting non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization, in addition to the Company’s GAAP gross profit and gross margin, provides a better understanding of the underlying trends in the Company’s operating business performance.

Reconciliation of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are set forth at the end of this press release, all of which should be considered when evaluating the Company’s performance.

Contact: [email protected]



Selected Operating Data

      As of      
  March
31, 2023
  June
30, 2023
  September
30, 2023
  December
31, 2023
  March
31, 2024
  June 30,

2024
  September
30, 2024
  December
31, 2024
In-hospital channel:                              
Pipeline partner hospitals(1) 29   30   29   28   28   29   30   29
Contracted partner hospitals(2) 49   50   55   59   59   59   61   63
Total number of partner
hospitals
78   80   84   87   87   88   91   92

(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company’s products.
(2) Refers to hospitals that have entered into contracts to purchase the Company’s products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals.

Selected Financial Data

      For the three months ended      
Revenues

March 31,
2023
  June 30,
2023
  September 30,
2023
  December 31,
2023
  March 31,

2024
  June 30,

2024
  September 30,
2024
  December 31,
2024
  (RMB in thousands)  
Central laboratory channel 61,804   66,239   53,481   51,288   47,614   48,773   39,984   39,278
In-hospital channel 51,561   53,835   54,496   28,809   57,387   59,872   63,769   43,464
Pharma research and development channel 29,151   26,194   19,589   40,988   20,622   26,888   24,891   43,280
Total revenues 142,516   146,268
  127,566
  121,085   125,623   135,533   128,644   126,022

                                        

      For the three months ended      
Gross profit

March 31,
2023
  June 30,
2023
  September 30,
2023
  December 31,
2023
  March 31,

2024
  June 30,

2024
  September 30,
2024
  December 31,
2024
  (RMB in thousands)  
Central laboratory channel 48,090   51,876   41,487   41,886   37,002   38,424   33,262   33,153
In-hospital channel 34,409   33,353   35,459   12,910   39,192   44,058   46,580   29,563
Pharma research and development channel 16,273   15,193   8,974   23,317   9,500   12,956   12,004   26,706
Total gross profit
98,772   100,422   85,920   78,113   85,694   95,438   91,846   89,422

      For the three months ended      
Share-based compensation expenses
March 31,
2023
  June 30,
2023
  September 30,
2023
  December 31,
2023
  March 31,

2024
  June 30,

2024
  September 30,
2024
  December 31,
2024
  (RMB in thousands)  
Cost of revenues 353   627   680   654   596   464   289   520
Research and development expenses 13,612   15,301   12,161   12,401   12,287   12,008   3,180   3,202
Selling and marketing expenses 1,606   3,389   2,848   1,816   508   1,232   1,917   1,353
General and administrative expenses 62,595   18,502   57,704   56,472   55,990   54,407   4,732   2,937
Total share-based compensation expenses
78,166   37,819   73,393   71,343   69,381   68,111   10,118   8,012

Burning Rock Biotech Limited

Unaudited Condensed Statements of Comprehensive Loss

(in thousands, except for number of shares and per share data)
 
  For the three months ended
  March
31, 2023



  June
30, 2023



  September
30, 2023



  December
31, 2023



  March
31, 2024



  June
30, 

2024


  September
30, 2024



  December
31, 2024



  December
31, 2024



  RMB RMB RMB RMB RMB RMB RMB RMB US$
Revenues 142,516     146,268     127,566     121,085     125,623     135,533     128,644     126,022     17,265  
Cost of revenues (43,744 )   (45,846 )   (41,646 )   (42,972 )   (39,929 )   (40,095 )   (36,798 )   (36,600 )   (5,014 )
Gross profit 98,772     100,422     85,920     78,113     85,694     95,438     91,846     89,422     12,251  
Operating expenses:                  
Research and development expenses (94,417 )   (95,779 )   (83,701 )   (73,119 )   (65,985 )   (64,952 )   (49,150 )   (52,203 )   (7,152 )
Selling and marketing expenses (64,774 )   (70,842 )   (62,310 )   (49,785 )   (46,856 )   (48,907 )   (48,411 )   (46,730 )   (6,402 )
General and administrative expenses (128,039 )   (69,525 )   (118,724 )   (121,533 )   (98,681 )   (92,794 )   (32,874 )   (37,289 )   (5,109 )
Impairment loss on long-lived assets                             (35,127 )   (4,812 )
Total operating expenses (287,230 )   (236,146 )   (264,735 )   (244,437 )   (211,522 )   (206,653 )   (130,435 )   (171,349 )   (23,475 )
Loss from operations  (188,458 )   (135,724 )   (178,815 )   (166,324 )   (125,828 )   (111,215 )   (38,589 )   (81,927 )   (11,224 )
Interest income 3,144     5,255     4,018     5,539     4,038     3,187     3,173     1,814     249  
Other income (expense), net 599     (118 )   (157 )   160     434     (82 )   1     4,353     596  
Foreign exchange (loss) gain, net (116 )   (210 )   423     (517 )   (13 )   262     (129 )   (220 )   (30 )
Loss before income tax (184,831 )   (130,797 )   (174,531 )   (161,142 )   (121,369 )   (107,848 )   (35,544 )   (75,980 )   (10,409 )
Income tax expenses (422 )   (445 )   (450 )   (1,071 )   (180 )   (190 )   (201 )   (5,314 )   (728 )
Net loss (185,253 )   (131,242 )   (174,981 )   (162,213 )   (121,549 )   (108,038 )   (35,745 )   (81,294 )   (11,137 )
Net loss attributable to Burning Rock Biotech Limited’s shareholders (185,253 )   (131,242 )   (174,981 )   (162,213 )   (121,549 )   (108,038 )   (35,745 )   (81,294 )   (11,137 )
Loss per share for class A and class B ordinary shares:                  
Class A ordinary shares – basic and diluted (1.81 )   (1.28 )   (1.71 )   (1.58 )   (1.19 )   (1.05 )   (0.35 )   (0.79 )   (0.11 )
Class B ordinary shares – basic and diluted (1.81 )   (1.28 )   (1.71 )   (1.58 )   (1.19 )   (1.05 )   (0.35 )   (0.79 )   (0.11 )
Weighted average shares outstanding used in loss per share computation:                  
Class A ordinary shares – basic and diluted 85,065,585     85,151,052     85,000,869     85,071,360     85,219,188     85,271,858     85,902,670     86,036,286     86,036,286  
Class B ordinary shares – basic and diluted 17,324,848     17,324,848     17,324,848     17,324,848     17,324,848     17,324,848     17,324,848     17,324,848     17,324,848  
Other comprehensive (loss) income, net of tax of nil:                  
Foreign currency translation adjustments (5,659 )   14,829     (1,955 )   (3,026 )   590     940     (4,054 )   6,009     823  
Total comprehensive loss (190,912 )   (116,413 )   (176,936 )   (165,239 )   (120,959 )   (107,098 )   (39,799 )   (75,285 )   (10,314 )
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders (190,912 )   (116,413 )   (176,936 )   (165,239 )   (120,959 )   (107,098 )   (39,799 )   (75,285 )   (10,314 )

Burning Rock Biotech Limited

Unaudited Condensed Statements of Comprehensive Loss

(in thousands, except for number of shares and per share data)
   
  For the year ended
  December 31,

2023


  December 31,

2024


  December 31,

2024


  RMB


  RMB


  US$


Revenues 537,435     515,822     70,667  
Cost of revenues (174,208 )   (153,422 )   (21,020 )
Gross profit 363,227     362,400     49,647  
Operating expenses:      
Research and development expenses (347,016 )   (232,290 )   (31,824 )
Selling and marketing expenses (247,711 )   (190,904 )   (26,154 )
General and administrative expenses (437,821 )   (261,638 )   (35,844 )
Impairment loss on long-lived assets     (35,127 )   (4,812 )
Total operating expenses (1,032,548 )   (719,959 )   (98,634 )
Loss from operations  (669,321 )   (357,559 )   (48,987 )
Interest income 17,956     12,212     1,673  
Other income, net 484     4,706     645  
Foreign exchange loss, net (420 )   (100 )   (14 )
Loss before income tax (651,301 )   (340,741 )   (46,683 )
Income tax expenses (2,388 )   (5,885 )   (806 )
Net loss (653,689 )   (346,626 )   (47,489 )
Net loss attributable to Burning Rock Biotech Limited’s shareholders (653,689 )   (346,626 )   (47,489 )
Loss per share for class A and class B ordinary shares:      
Class A ordinary shares – basic and diluted (6.38 )   (3.37 )   (0.46 )
Class B ordinary shares – basic and diluted (6.38 )   (3.37 )   (0.46 )
Weighted average shares outstanding used in loss per share computation:      
Class A ordinary shares – basic and diluted 85,071,691     85,610,197     85,610,197  
Class B ordinary shares – basic and diluted 17,324,848     17,324,848     17,324,848  
Other comprehensive income, net of tax of nil:      
Foreign currency translation adjustments 4,189     3,485     477  
Total comprehensive loss (649,500 )   (343,141 )   (47,012 )
Total comprehensive loss attributable to Burning Rock Biotech Limited’s shareholders (649,500 )   (343,141 )   (47,012 )

Burning Rock Biotech Limited

Unaudited Condensed Consolidated Balance Sheets

(In thousands)

 
  As of
  December 31,

2023
  December 31,

2024
  December 31,

2024
  RMB   RMB   US$
ASSETS          
Current assets:          
Cash and cash equivalents 615,096   519,849   71,219
Restricted cash 120   2,313   317
Accounts receivable, net 126,858   152,013   20,826
Contract assets, net 22,748   13,855   1,898
Inventories, net 69,020   62,625   8,580
Prepayments and other current assets 50,254   25,963   3,557
Total current assets 884,096   776,618   106,397
Non-current assets:          
Equity method investment 337    
Convertible note receivable 5,320    
Property and equipment, net 131,912   47,152   6,460
Operating right-of-use assets 12,284   53,188   7,287
Intangible assets, net 964   421   58
Other non-current assets 5,088   7,926   1,086
Total non-current assets 155,905   108,687   14,891
TOTAL ASSETS   1,040,001   885,305   121,288

Burning Rock Biotech Limited

Unaudited Condensed Consolidated Balance Sheets (Continued)

(in thousands)

 
  As of
  December 31,

2023


  December 31,

2024


  December 31,

2024


  RMB


  RMB


  US$


LIABILITIES AND SHAREHOLDERS’ EQUITY      
Current liabilities:      
Accounts payable 18,061     33,747     4,623  
Deferred revenue 130,537     117,895     16,152  
Accrued liabilities and other current liabilities 104,935     89,498     12,262  
Customer deposits 1,197     592     81  
Current portion of operating lease liabilities 8,634     24,567     3,366  
Total current liabilities 263,364     266,299     36,484  
Non-current liabilities:      
Non-current portion of operating lease liabilities 3,690     27,754     3,802  
Other non-current liabilities 4,537     10,425     1,428  
Total non-current liabilities 8,227     38,179     5,230  
TOTAL LIABILITIES 271,591     304,478     41,714  

Shareholders’ equity:

     
Class A ordinary shares 116     124     17  
Class B ordinary shares 21     21     3  
Additional paid-in capital 4,849,337     5,002,255     685,306  
Treasury stock (65,896 )   (63,264 )   (8,667 )
Accumulated deficits (3,853,635 )   (4,200,261 )   (575,433 )
Accumulated other comprehensive loss (161,533 )   (158,048 )   (21,652 )
Total shareholders’ equity 768,410     580,827     79,574  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 1,040,001     885,305     121,288  

Burning Rock Biotech Limited

Unaudited Condensed Statements of Cash Flows

(in thousands)

 
  For the three months ended
  December 31,

2023 
  December 31,

2024 
  December 31,

2024 
  RMB     RMB    US$ 
Net cash (used in) generated from operating activities (16,019 )   19,062     2,611  
Net cash used in investing activities (328 )   (812 )   (111 )
Net cash used in financing activities (1,909 )   (74 )   (10 )
Effect of exchange rate on cash, cash equivalents and restricted cash (3,277 )   5,739     787  
Net (decrease) increase in cash, cash equivalents and restricted cash (21,533 )   23,915     3,277  
Cash, cash equivalents and restricted cash at the beginning of period 636,749     498,247     68,259  
Cash, cash equivalents and restricted cash at the end of period 615,216     522,162     71,536  
       

  For the year ended
  December 31,

2023


  December 31,

2024


  December 31,

2024


  RMB


  RMB


  US$


Net cash used in operating activities (255,783 )   (92,261 )   (12,640 )
Net cash used in investing activities (9,300 )   (4,412 )   (604 )
Net cash used in financing activities (48,832 )   (72 )   (10 )
Effect of exchange rate on cash, cash equivalents and restricted cash 3,863     3,691     506  
Net decrease in cash, cash equivalents and restricted cash (310,052 )   (93,054 )   (12,748 )
Cash, cash equivalents and restricted cash at the beginning of period 925,268     615,216     84,284  
Cash, cash equivalents and restricted cash at the end of period 615,216     522,162     71,536  

Burning Rock Biotech Limited

Reconciliations of GAAP and Non-GAAP Results

 
   For the three months ended
  March 31,
2023



  June 30,
2023



  September 30,
2023



  December 31,
2023



  March 31,

2024


  June 30,

2024


  September 30,
2024



  December 31,
2024



    (RMB in thousands)  
Gross profit:
     
Central laboratory channel 48,090   51,876   41,487   41,886   37,002   38,424   33,262   33,153  
In-hospital channel 34,409   33,353   35,459   12,910   39,192   44,058   46,580   29,563  
Pharma research and development channel 16,273   15,193   8,974   23,317   9,500   12,956   12,004   26,706  
Total gross profit
98,772   100,422   85,920   78,113   85,694   95,438   91,846   89,422  
Add: depreciation and amortization:                
Central laboratory channel 2,567   2,645   2,550   2,414   1,919   1,226   1,277   1,010  
In-hospital channel 2,582   2,637   2,751   2,728   1,524   824   798   623  
Pharma research and development channel 3,974   3,665   3,863   3,808   3,856   4,417   3,846   2,534  
Total depreciation and amortization included in cost of revenues
9,123   8,947   9,164   8,950   7,299   6,467   5,921   4,167  
Non-GAAP gross profit:                
Central laboratory channel 50,657   54,521   44,037   44,300   38,921   39,650   34,539   34,163  
In-hospital channel 36,991   35,990   38,210   15,638   40,716   44,882   47,378   30,186  
Pharma research and development channel 20,247   18,858   12,837   27,125   13,356   17,373   15,850   29,240  
Total non-GAAP gross profit 107,895   109,369
  95,084
  87,063   92,993   101,905   97,767   93,589  
Non-GAAP gross margin:                
Central laboratory channel 82.0%   82.3%   82.3%   86.4%   81.7%   81.3%   86.4%   87.0%  
In-hospital channel 71.7%   66.9%   70.1%   54.3%   70.9%   75.0%   74.3%   69.5%  
Pharma research and development channel 69.5%   72.0%   65.5%   66.2%   64.8%   64.6%   63.7%   67.6%  
Total non-GAAP gross margin 75.7
%
  74.8
%
  74.5
%
  71.9
%
  74.0
%
  75.2
%
  76.0
%
  74.3
%
 

Burning Rock Biotech Limited

Reconciliations of GAAP and Non-GAAP Results

 
  For the year ended
  December 31,
2023



  December 31,
2024



  (RMB in thousands)
Gross profit:
   
Central laboratory channel 183,339   141,841
In-hospital channel 116,131   159,393
Pharma research and development channel 63,757   61,166
Total gross profit
363,227   362,400
Add: depreciation and amortization:    
Central laboratory channel 10,176   5,432
In-hospital channel 10,699   3,769
Pharma research and development channel 15,310   14,653
Total depreciation and amortization included in cost of revenues
36,185   23,854
Non-GAAP gross profit:    
Central laboratory channel 193,515   147,273
In-hospital channel 126,830   163,162
Pharma research and development channel 79,067   75,819
Total non-GAAP gross profit 399,412   386,254
Non-GAAP gross margin:    
Central laboratory channel 83.1%   83.8%
In-hospital channel 67.2%   72.7%
Pharma research and development channel 68.2%   65.5%
Total non-GAAP gross margin 74.3
%
  74.9
%



Starwood Property Trust Announces Private Offering of Sustainability Bonds

PR Newswire


MIAMI BEACH, Fla.
, March 25, 2025 /PRNewswire/ — Starwood Property Trust, Inc. (NYSE: STWD) (the “Company”) today announced that, subject to market and other conditions, it is offering $400 million aggregate principal amount of its unsecured senior notes due 2030 (the “Notes”) in a private offering.

The Company intends to allocate an amount equal to the net proceeds from the offering to finance or refinance, in whole or in part, recently completed or future eligible green and/or social projects. Net proceeds allocated to previously incurred costs associated with eligible green and/or social projects will be available for the repayment of indebtedness previously incurred. Pending full allocation of an amount equal to the net proceeds to eligible green and/or social projects, the Company intends to use the net proceeds for general corporate purposes, which may include the repayment of outstanding indebtedness under the Company’s repurchase facilities.

The Notes will be offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and non-U.S. persons outside the United States pursuant to Regulation S under the Securities Act. The Notes will not initially be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from the registration requirements of the Securities Act or any state securities laws.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Starwood Property Trust, Inc.

Starwood Property Trust, Inc. (NYSE: STWD), an affiliate of global private investment firm Starwood Capital Group, is a leading diversified finance company with a core focus on the real estate and infrastructure sectors. As of December 31, 2024, the Company has successfully deployed over $102 billion of capital since inception and manages a portfolio of $25 billion across debt and equity investments. Starwood Property Trust’s investment objective is to generate attractive and stable returns for shareholders, primarily through dividends, by leveraging a premiere global organization to identify and execute on the best risk adjusted returning investments across its target assets.

Forward-Looking Statements

Statements in this press release which are not historical fact may be deemed forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to the anticipated offering and the use of proceeds. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained.  Factors that could cause actual results to differ materially from the Company’s expectations include: (i) factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, including those set forth under the captions “Risk Factors”, “Business”, and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; (ii) defaults by borrowers in paying debt service on outstanding indebtedness; (iii) impairment in the value of real estate property securing the Company’s loans or in which the Company invests; (iv) availability of mortgage origination and acquisition opportunities acceptable to the Company; (v) potential mismatches in the timing of asset repayments and the maturity of the associated financing agreements; (vi) national and local economic and business conditions, including as a result of the impact of public health emergencies; (vii) the occurrence of certain geo-political events (such as wars, terrorist attacks and tensions between states, including global trade disputes related to tariffs) that affect the normal and peaceful course of international relations; (viii) general and local commercial and residential real estate property conditions; (ix) changes in federal government policies; (x) changes in federal, state and local governmental laws and regulations; (xi) increased competition from entities engaged in mortgage lending and securities investing activities; (xii) changes in interest rates; and (xiii) the availability of, and costs associated with, sources of liquidity.

Contact:

Zachary Tanenbaum

Starwood Property Trust
Phone: 203-422-7788
Email: [email protected]

 

Cision View original content:https://www.prnewswire.com/news-releases/starwood-property-trust-announces-private-offering-of-sustainability-bonds-302410564.html

SOURCE Starwood Property Trust, Inc.

ZenaTech’s ZenaDrone Developing Indoor Drone Swarm Application for Inventory Management and Security with Auto Parts Manufacturer Customer

VANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, today announces its subsidiary ZenaDrone is developing a drone swarm application using multiple indoor IQ Nano drones for inventory management and security applications. ZenaDrone is conducting this development with its auto parts manufacturer customer where it is currently engaged in a paid trial.

A drone swarm is a coordinated group of autonomous drones that communicate and work together using AI and real-time data sharing, to perform tasks collaboratively without direct human control. Drone swarms can enhance efficiency, accuracy, automation and performance compared to a single drone.

“We are pioneering the development of autonomous drone swarm technology, revolutionizing indoor inventory management and warehouse security by providing real-time, more accurate stock tracking and surveillance with reduced manual processes. We believe this technology will enable warehouses to operate more efficiently, reduce costs, and enhance safety and security while setting a new industry standard for AI drones,” said CEO Shaun Passley, Ph.D.

Using multiple drones or a drone swarm for indoor inventory management—such as reading barcodes or RFID tags—may offer significant advantages in efficiency, accuracy, and scalability. Autonomous drones can rapidly scan thousands of tags per second with high accuracy, providing real-time visibility into inventory without disrupting workflows. This is particularly valuable in large warehouses where manual stocktaking is time-consuming and labor-intensive. A drone swarm can also cover more ground simultaneously, dramatically reducing inventory audit times while providing near-total inventory visibility.

An AI drone swarm for indoor security and surveillance enhances coverage, response time, and efficiency by autonomously patrolling large areas, detecting threats, and providing real-time situational awareness. Unlike stationary cameras or human patrols, drone swarms can dynamically adapt to security breaches, track intruders, and coordinate movements to eliminate blind spots. AI-driven analytics enable them to identify anomalies, recognize faces, and detect unauthorized activity with high precision, reducing false alarms and improving security decision-making. Their autonomous nature minimizes human labor costs while ensuring 24/7 monitoring in complex environments like warehouses, data centers, or commercial facilities.

The ZenaDrone IQ Nano is available in 10×10 and 20×20-inch sizes, designed to perform regular and frequent inspections such as bar code or RFID scanning, facility maintenance inspections, security monitoring, 3D indoor mapping and other applications inside a warehouse, distribution, or plant facility. The IQ Nano is designed for autonomous use featuring integrated sensors, high-quality cameras, data collection and analysis including artificial intelligence methodologies. Weighing 1.5kg and with a flight time of at least 20 minutes before utilizing the automatic battery recharging station, it is designed for hovering stability and safety with obstacle avoidance capabilities.

About ZenaTech

ZenaTech (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical business applications. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, health, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive exceptional operational efficiencies, accuracy and cost savings. The Company operates through seven global offices in North America, Europe, Taiwan, and UAE, and is growing a DaaS business model and global partner network.

About ZenaDrone

ZenaDrone, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous business drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for industrial surveillance, monitoring, inspection, tracking, process automation and defense applications. Currently, the ZenaDrone 1000 drone is used for crop management applications in agriculture and critical field cargo applications in the defense sector, the IQ Nano indoor drone is used for inventory management and security in the warehouse and logistics sectors, and the IQ Square is an indoor/outdoor drone designed for land survey and inspections use in commercial and defense sectors.

Contacts for more information:

Company, Investors and Media:

Linda Montgomery
ZenaTech
312-241-1415
[email protected]

Investors:

Michael Mason
CORE IR
[email protected]

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements.  Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000 and IQ Nano; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech. 



OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

OS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers

Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd

NEW YORK–(BUSINESS WIRE)–
OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2. The movie will premiere on April 3, 2025 at AMC Century City in Los Angeles and will be available to stream through the PBS app and on PBS.org starting in May.

“Our team is dedicated to advancing a treatment for osteosarcoma and are proud to see our immunotherapy in Shelter Me: The Cancer Pioneers,” stated OS Therapies’ CEO Paul Romness. “Comparative oncology is an important area of research for us because of the striking genetic homology of over 96% between human and canine osteosarcoma.” OST-HER2 is an investigational drug and is not currently approved to treat osteosarcoma or any other disease.

Shelter Me: The Cancer Pioneers also features leading scientists at the National Cancer Institute / National Institutes of Health, the University of Pennsylvania, the University of Illinois, the University of Wisconsin, and Colorado State University. It is part of an Emmy Award-winning PBS series, Shelter Me, that celebrates the life-changing relationships between people and animals.

A trailer of the movie can be viewed here.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.

In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

OS Therapies Contact Information:

Jack Doll

571.243.9455

[email protected]

https://x.com/OSTherapies

https://www.instagram.com/ostherapies/

https://www.facebook.com/OSTherapies/

https://www.linkedin.com/company/os-therapies/

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Research Entertainment Film & Motion Pictures Pharmaceutical Oncology Consumer TV and Radio Science Veterinary Biotechnology Health Pets Other Science

MEDIA:

Logo
Logo